ZELTIQ

A COOL SUCCESS STORY

Mark Foley President & CEO

THE CULMINATION

February 13, 2017

Allergan (AGN) to Acquire ZELTIQ, Best-in-Class Company in

Fast-Growing Body Contouring Segment for \$2.475 Billion



- \$56.50 per share
- ~7x 2016 revenue
- Immediately accretive all cash transaction expected to close in 2H 2017

THE PROGRESSION



What strategic decisions evolved **ZELTIQ** from a concept...

\$354M

To the best-in class body contouring company with >\$350M in revenue and a \$2.5B valuation?



Historical Overview

Genesis

Business Disruption

Lessons Learned



COOLSCULPTING TECHNOLOGY

- Fat cells are hypersensitive to cold more so than skin, nerves, muscles
 - 1970 Popsicle panniculitis
 - 1980 Equestrian cold panniculitis
- Strong science and IP
- Novel and differentiated approach in new market category





FAT FREEZING DURING COOLSCULPTING





Many of us have stubborn fat despite diet and exercise. CoolSculpting technology uses controlled cooling to target and kill only these fat cells.

In the weeks to follow, your body naturally processes the fat and eliminates dead cells.



* Bernstein EF, Long-term efficacy follow-up on two cryolipolysis case studies: 6 and 9 years post-treatment. Journal of Cosmetic Dermatology. 2016

COMPANY EVOLUTION



FUNDAMENTAL QUESTIONS



Business Disruption

Missed first two quarters (Q4 2011 and Q1 2012) as a public company

Competitive disruption
Burning cash

Historical performance by aesthetic "box" companies created understandable investor skepticism and concern



KEY AREAS OF FOCUS

New interim CEO announced Is this a technology or an execution issue?

 Do we have the right commercialization strategy, structure, and people?

Stabilize the organization

Control cash burn

Lessons Learned

 Is this a technology or an execution issue?

 Do we have the right commercialization strategy, structure, and people?

Stabilize the organization

Control cash burn

Discussions with key customers indicated they were experiencing success

Technology was not the issue. Execution and training were inconsistent.

FOCUSED ON OUTCOMES



- Created a new treatment protocol
- Developed CoolSculpting University (CSU) to drive consistent training
 - Program launch followed successful pilot

 Is this a technology or an execution issue?

 Do we have the right commercialization strategy, structure, and people?

Stabilize the organization

Control cash burn

COMMERCIALIZATION ACTION PLAN

- Bifurcated sales team, creating capital and consumable reps
 - Enabled capital reps to build a pipeline of customers – longer lead time
 - Focused consumable reps on practice and marketing support, training
- Brought in experienced leadership
- Reorganized under one global leader to focus on North America
- Changed compensation structure



Stabilize the organization

Control cash burn

STABILIZATION PLAN

- Very transparent with initiatives and process
- Some personnel changes
- Maintained a clear vision



Control cash burn

INVESTMENT PRIORITIZATION PLAN

- Pulled back on DTC
 - Needed broader installed base and training to drive more consistent conversion
 - Focused on co-op advertising
- North America focus
- Streamlined R&D focus
- Streamlined organizational structure
- Pilot programs before full implementation







Key Strategic Decisions



2 Key Strategic Decisions

Focus

Consumable Model Strategy

New Product Consistency

Talent Management



FOCUS- HELPED DRIVE CONSISTENT AND SUSTAINABLE GROWTH

- CoolSculpting vs diversification?
- Disciplined new box placements vs accelerated placements (sales force expansion)?
- North America vs International?
- Growth vs Profitability

coolsculpting



2 Key Strategic Decisions

Focus

Consumable Model Strategy

New Product Consistency

Talent Management

Consumable Model Strategy

CONSUMABLE MODEL DECISIONS

- Discount?
- Give away?
- Raise price?



- Created win/win partnership with our customers
 - Reinvested annuity stream to create value and drive success
 - Protected the brand
ZELTIQ REINVESTMENT



Practice Development Managers Dedicated PDMs incentivized by the success of their practices' business.

Brand Advertising

National DTC campaign grew average practice revenue significantly.



CoolConnect Connectivity platform enables practices to analyze and measure the success of their business.

GROWTH



Process for Success "5 Steps to Success" proven

recipe to reach \$260K in revenue in the first 12 mos.

CoolSculpting University[™]

Industry-leading training program with proven results driving CoolSculpting practice volume.

EDUCATION

Proven Technology

4M+

Treatment

Cycles

70+

Peer-

Studies

Reviewed

Crystal Rewards[™] Co-op program shares costs of building awareness.



PROTECTION

Cool AssuranceTM Warranty program



protects practice investment.

Minimum Advertised Price

Pricing policy maintains brand and pricing integrity.





2 Key Strategic Decisions

Focus

Consumable Model Strategy

New Product Consistency

Talent Management

New Product Consistency

STEADY PRODUCT NEWNESS



THOUGHTFUL INNOVATION

New Product Goals:

- Improve user experience and market efficacy
- Layer launch timing with spring and fall trade shows to drive excitement
- New applicators backward compatible with existing control unit





2 Key Strategic Decisions

Focus

Consumable Model Strategy

New Product Consistency

Talent Management

Talent Management

PEOPLE AND STRUCTURE

- Organizational change is less complicated during challenging times
- Success dictates evolutionary, not revolutionary change
- Talent choices made with business growth goals in mind

2012: REVOLUTIONARY ORGANIZATIONAL CHANGE

- Executive team:
 - · CEO, CFO, CTO, CMO, HR, SVP S&M, VP Op's
- Industry expertise
 - Brought in leadership with aesthetic capital expertise
- Structure:
 - Restructured marketing dept and personnel
 - Consolidated global sales organization
- Organization:
 - ~65% of organization and 80% of sales force hired by new management team
 - Focus on culture



LEADERSHIP-DRIVEN CULTURE



Customer-centric

Entire company focused on clinical outcomes Flat Structure

Goal of leadership is removal of obstacles so others can get work done Family environment

Emphasize work-life balance in tandem with performance culture Aligned Vision

Company-wide goal setting, shared achievements Performance Pay

All employees given equity when they join



Brand Building

Fortified Culture

Financial Execution

Stock Performance

Successful Outcomes

Premium Valuation

Brand Building



* One million patient figure assumes 4 cycles per patient

UTILIZATION EXPANSION

Global Revenue Cycles/ Account/ Day





ONLINE VALIDATION



COOLSCULPTING® VOTED THE BEST!

CoolSculpting was named the "Best Non-Novasive Fat Reducer" for the third consecutive year in the NewBeauty Annual Beauty Choice Awards.

SEE MORE MEDIA BUZZ





PATIENT VALIDATION

realself "Worth it" Rating January 2017 (last 12 months)



"My results are beyond what I thought they would be. My thighs have been an area of concern for me since I was a little girl post puberty and I am so happy to have room down there now." "I am 6 weeks on Thursday and I can see a difference in my clothes. Friends have noticed a difference as well... I am really happy with the process so far. It was **definitely worth the money**!"

Brand Building

Fortified Culture

Financial Execution

Stock Performance

Successful Outcomes

Premium Valuation

Fortified Culture

EXPONENTIAL WORKFORCE GROWTH



ZELTIQ Aesthetics Ratings and Trends from Glassdoor.com







"Get Zeltig'ized!!!"

🗙 🗙 ★ ★ 🔻 Current Employee - Anonymous Employee

Recommends

Positive Outlook

Approves of CEO

Pros

*Good HR packages/programmes *Diverse Teams /multilingual/multicultural *Energetic and inspirational environment *fast growing *room for development *"avantgardistic" *living the company vision

Cons

*are there any? Not for me, lucky me has the Jackpot with the Team I am in!!! Yes, there is such a thing as having amazing supervisors - and inspirational LEADERS in the Management! ***Leading by exampel***

This company is so COOL it roxx!!!!

Advice to Management

*order automation would make a huge difference in resources/TIME (been there done that! Successfully and happy mind you)

*we should start using the full capacity of our already existing systems (as we are using the supreme systems already !! --> SAP, Salesforce), rather then implementing new ones...... *want to take the opportunity to say THANK YOU - for letting me be a part in this corporation family! My Team as well as the whole UNIT are awesome spirited people.

Financial Execution

SOLID REVENUE GROWTH



ZELTIQ outperformed **First Call expectations** in every quarter from Q1 2013 through its final public quarter in Q4 2016

REVENUE OUTPERFORMANCE



* First Call Consensus calculated on an average basis based off all available analyst estimates. For 2013, estimates are sourced from analyst reports following 4Q12 and FY12 results. For 2014-2015, estimates are blended from analyst reports following 4Q12 and FY12 results and analyst reports following 4Q13 and FY13 results. For 2016, estimates are sourced from analyst reports following 4Q13 and FY13 results.

With the \$354M in revenue achieved in FY2016, ZELTIQ exceeded Wall Street expectations for the company following the leadership change in 2012 by $\sim 90\%$

Brand Building

Fortified Culture

Financial Execution

Stock Performance

Successful Outcomes

Premium Valuation

Stock Performance

EXCEPTIONAL PERFORMANCE



Since turnaround efforts began in 2012, ZLTQ's stock returned over 10x!

HOW DOES THAT COMPARE TO THE OTHER MED DEVICE IPO'S?*

Total Return (IPO Date to 2/17/17)



*Since 2011. Computed 2/7/17 prior to acquisition impact on ZELTIQ stock price.

Premium Valuation

VALUE CREATION

At 7×2016 revenues, the purchase price for ZELTIQ speaks to the value created by thoughtful decisions and execution

Period	Mean/Median	Transaction Value (\$MM)	TEV/REV	TEV/EBITDA
2016 2016	Mean	\$184.8	3.11x	15.03x
	Median	\$28.1	2.24x	12.70x
2015 2015	Mean	\$229.0	4.68x	16.06x
	Median	\$27.2	2.20x	12.10x
2014	Mean	\$194.2	6.43x	16.68x
2014	Median	\$23.0	2.14x	12.50x
2013 2013	Mean	\$132.2	6.02x	13.15x
	Median	\$19.0	2.04x	12.20x
2012	Mean	\$190.5	2.63x	14.17x
2012	Median	\$21.7	1.88x	11.50x

Source: S&P Capital IQ, PMCF Note: Certain outliers have been removed

Why the premium valuation?

ZELTIQ'S ACHIEVEMENTS PROPELLED THE COMPANY INTO AN ELITE CLASS

Medical Device IPO's Since 2011 # of companies: 22

> Achieved Market Cap > \$1.5B 6



^ CAGR from 2014 to 2016* On EBITDA basis

Every company faces critical decisions

Some are obvious:

\checkmark Clinical trial design

Regulatory/ reimbursement strategy



Others are less obvious:

Focus or diversify?

Allocation of resources

Growth vs profitability

KEYS TO SUCCESS FROM THE ZELTIQ EXPERIENCE

